BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 17464295)

  • 1. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.
    Szallasi A; Cortright DN; Blum CA; Eid SR
    Nat Rev Drug Discov; 2007 May; 6(5):357-72. PubMed ID: 17464295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRPV1: a therapeutic target for novel analgesic drugs?
    Szallasi A; Cruz F; Geppetti P
    Trends Mol Med; 2006 Nov; 12(11):545-54. PubMed ID: 16996800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRPV1 antagonists: the challenges for therapeutic targeting.
    Khairatkar-Joshi N; Szallasi A
    Trends Mol Med; 2009 Jan; 15(1):14-22. PubMed ID: 19097938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
    Wong GY; Gavva NR
    Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
    Knotkova H; Pappagallo M; Szallasi A
    Clin J Pain; 2008 Feb; 24(2):142-54. PubMed ID: 18209521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
    Gunthorpe MJ; Chizh BA
    Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
    Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
    J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain TRPV1: a depressing TR(i)P down memory lane?
    Di Marzo V; Gobbi G; Szallasi A
    Trends Pharmacol Sci; 2008 Dec; 29(12):594-600. PubMed ID: 18947889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
    Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
    Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Answering the burning question of how transient receptor potential vanilloid-1 channel antagonists cause unwanted hyperthermia.
    Ayoub SS; Hunter JC; Simmons DL
    Pharmacol Rev; 2009 Sep; 61(3):225-7. PubMed ID: 19805475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
    Voight EA; Kort ME
    Expert Opin Ther Pat; 2010 Sep; 20(9):1107-22. PubMed ID: 20586701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
    Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
    J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation.
    Alawi K; Keeble J
    Pharmacol Ther; 2010 Feb; 125(2):181-95. PubMed ID: 19896501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
    Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
    J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1.
    Gavva NR
    Trends Pharmacol Sci; 2008 Nov; 29(11):550-7. PubMed ID: 18805596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
    Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
    J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
    Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
    J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.
    Culshaw AJ; Bevan S; Christiansen M; Copp P; Davis A; Davis C; Dyson A; Dziadulewicz EK; Edwards L; Eggelte H; Fox A; Gentry C; Groarke A; Hallett A; Hart TW; Hughes GA; Knights S; Kotsonis P; Lee W; Lyothier I; McBryde A; McIntyre P; Paloumbis G; Panesar M; Patel S; Seiler MP; Yaqoob M; Zimmermann K
    J Med Chem; 2006 Jan; 49(2):471-4. PubMed ID: 16420034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRPV1 receptors in sensitisation of cough and pain reflexes.
    Adcock JJ
    Pulm Pharmacol Ther; 2009 Apr; 22(2):65-70. PubMed ID: 19141328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans.
    Gavva NR; Treanor JJ; Garami A; Fang L; Surapaneni S; Akrami A; Alvarez F; Bak A; Darling M; Gore A; Jang GR; Kesslak JP; Ni L; Norman MH; Palluconi G; Rose MJ; Salfi M; Tan E; Romanovsky AA; Banfield C; Davar G
    Pain; 2008 May; 136(1-2):202-10. PubMed ID: 18337008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.